Target family: Class A Orphans (type: gpcr)
Target: <i>GPR17</i>

Ligand: UDP-glucose (Metabolite)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Median affinity:  pEC50
Reference (Journal): The orphan receptor GPR17 identified as a new dual uracil nucleotides/cysteinyl-leukotrienes receptor.
Published in: EMBO J

Ligand: UDP-glucose (Metabolite)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Median affinity:  pEC50
Reference (Journal): Distinct expression and ligand-binding profiles of two constitutively active GPR17 splice variants.
Published in: Br J Pharmacol

Ligand: UDP-glucose (Metabolite)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Median affinity:  pEC50
Reference (Journal): The recently identified P2Y-like receptor GPR17 is a sensor of brain damage and a new target for brain repair.
Published in: PLoS ONE

Ligand: UDP-galactose (Metabolite)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Median affinity:  pEC50
Reference (Journal): Distinct expression and ligand-binding profiles of two constitutively active GPR17 splice variants.
Published in: Br J Pharmacol

Ligand: UDP-galactose (Metabolite)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Median affinity: 7.17 pEC50
Reference (Journal): The recently identified P2Y-like receptor GPR17 is a sensor of brain damage and a new target for brain repair.
Published in: PLoS ONE

Ligand: UDP-galactose (Metabolite)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Median affinity:  pEC50
Reference (Journal): The orphan receptor GPR17 identified as a new dual uracil nucleotides/cysteinyl-leukotrienes receptor.
Published in: EMBO J

Ligand: UDP (Metabolite)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Median affinity:  pEC50
Reference (Journal): The orphan receptor GPR17 identified as a new dual uracil nucleotides/cysteinyl-leukotrienes receptor.
Published in: EMBO J

Ligand: UDP (Metabolite)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Median affinity:  pEC50
Reference (Journal): Distinct expression and ligand-binding profiles of two constitutively active GPR17 splice variants.
Published in: Br J Pharmacol

Ligand: montelukast (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: yes
Approval source: FDA (1998)
Median affinity: 7.21 pIC50
Reference (Journal): The recently identified P2Y-like receptor GPR17 is a sensor of brain damage and a new target for brain repair.
Published in: PLoS ONE

Ligand: LTE4 (Metabolite)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Median affinity: 9.51 pEC50
Reference (Journal): The recently identified P2Y-like receptor GPR17 is a sensor of brain damage and a new target for brain repair.
Published in: PLoS ONE

Ligand: LTD4 (Metabolite)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Median affinity: 9.2 pEC50
Reference (Journal): The recently identified P2Y-like receptor GPR17 is a sensor of brain damage and a new target for brain repair.
Published in: PLoS ONE

Ligand: LTD4 (Metabolite)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Median affinity:  pEC50
Reference (Journal): The orphan receptor GPR17 identified as a new dual uracil nucleotides/cysteinyl-leukotrienes receptor.
Published in: EMBO J

Ligand: LTC4 (Metabolite)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Median affinity: 9.13 pEC50
Reference (Journal): The recently identified P2Y-like receptor GPR17 is a sensor of brain damage and a new target for brain repair.
Published in: PLoS ONE